摘要
背景与目的:乳腺癌是女性最常见多发的恶性肿瘤,化疗在乳腺癌治疗中占有重要的地位,本文旨在探讨基于三磷酸腺苷(adenosine triphosphate,ATP)的肿瘤化疗药物敏感性检测方法在乳腺癌药物筛选中的应用。方法:应用ATP-TCA法,检测50例乳腺癌标本体外对6种常用化疗药物和3种联合化疗方案的敏感性。结果:组织标本的可评估率为92%,多柔比星(ADM)联合紫杉醇(PTX)对乳腺癌细胞在体外抑制率最高,为95.3%;其次为ADM联合氟尿嘧啶(5-FU)为90.7%,多西他赛(TXT)为72.5%,PTX为70.7%,ADM为50.0%;甲氨蝶呤(MTX)联合5-FU为19.5%,MTX为9.8%。此外,化疗药物对乳腺癌细胞的杀伤作用具有较强的个体差异性。结论:ATP-TCA法操作简便,敏感性好,可能对临床个体化疗具有指导价值。
Background and purpose： Breast cancer has been the most common malignant tumor in women, and chemotherapy is an important treatment method for breast cancer. The purpose of this study was to investigate the chemosensitivity of the primary breast cancer through ATP-based tumor chemosensitivity assay （ATP-TCA）. Methods： Fifty breast cancer specimens were detected for chemosensitivity with 6 common chemotherapy drugs and 3 combination regimens by ATP-TCA. Results： A total number of 50 specimens were studied and 46 of these produced evaluable results （92%）. The cancer cells response to ADM＋PTX demonstrated the highest sensitivity （95.3%）, 90.7% for ADM＋5-FU, 72.5% for TXT, 70.7% for PTX, 50.0% for ADM, 19.5% for MTX＋5-FU and 9.8% for MTX. Breast cancer showed various chemosensitivities. Conclusion： ATP-TCA has shown sensitivity, stability, simplicity,rapidness and reliability. The assay might be used to guide individualized chemotherapy for patients with breast cancer.
出处
《中国癌症杂志》
CAS
CSCD
北大核心
2009年第11期871-874,共4页
China Oncology
关键词
乳腺癌
化疗
敏感性检测
breast cancer
chemotherapy
chemosensitivity
